Accelerate New York Seed Fund
VC Fund
Melville, United States
Accelerate New York Seed Fund is a VC fund in Melville focused on Health Care and Biotechnology. Accelerate NY Seed Fund supports science and technology-based early stage ventures. Provide critical seed and pre-seed funding for early stage growth.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Accelerate New York Seed Fund invests in
Stages Accelerate New York Seed Fund invests in
Countries Accelerate New York Seed Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Peter Donnelly
|
|||
Investment Focus
Industry
- Health Care 10 (45%)
- Biotechnology 7 (32%)
- Health Diagnostics 5 (23%)
- Medical 3 (14%)
- Software 3 (14%)
Stage
- Seed 17 (77%)
- Pre-Seed 2 (9%)
- Funding Round 2 (9%)
- Convertible Note 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Peter Donnelly
Managing Director
|
Managing Director | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cress Health
|
Cress Health develops disruptive technologies to enhance individual and organizational mental wellness. | Seed / Jan 01, 2022 | |
Fuell
|
Fuell the unifying idea: to create an urban mobility solution for cities.which is the best application of electric powertrains. The founders combined their experience and competences to invent a new experience entirely focused in the urban rider's needs | Seed / Jan 01, 2021 | |
Qunnect
|
Qunnect is a spin-off venture from the Quantum Information Technology group at Stony Brook university that focusses on engineering novel quantum devices enabling future information networks and quantum computing using photons to communicate and atoms to store and process quantum information. In particular, Qunnect focuses on engineering novelquantum memories and quantum sources that will enable future information networks and quantum computing. | $800K / Seed / Jan 07, 2020 | |
CalmiGo
|
CalmiGo is a natural, portable, and drug-free solution provider. It is a drug-free device and it is used for immediate relief of moments of distress, anxiousness, and stress by regulating the users'breathing patterns and senses, alleviating symptoms on the spot. | Seed / Jan 01, 2020 | |
Goldilocks Therapeutics
|
Goldilocks Therapeutics develop preventatives treatments for acute kidney injury, polycystic kidney disease, and other kidney conditions. The company uses its proprietary mesoscale nanoparticles (MNPs) specifically target therapeutic payloads to the renal tubule epithelium. It was founded in 2018 and is based in Bedford, New York. | Seed / Jan 01, 2020 | |
HashLynx
|
HashLynx will dramatically improve the efficiency and transparency of capital markets with our leading edge blockchain solutions and financial expertise. | Seed / Jan 01, 2019 | |
Aspisafe Solutions
|
Aspisafe Solutions is a medical device company focused on developing feeding medical devices such as catheters, feeding tubes, nasogastric tubes, and nasogastric tube holders. Aspisafe Solutions' flagship product is a nasogastric tube that prevents stomach reflux that reduces the chances of pneumonia. | Seed / Jan 01, 2019 | |
Toggle
|
How will we build the next generation of cities and infrastructure when key construction methods have remained unchanged for a generation? As the built environment grows larger and more complex Toggle is introducing industrial robotics and automation to critical construction methods and materials. Starting with rebar for reinforced concrete Toggleis reinventing the way we build our world. | $570K / Pre-Seed / Nov 10, 2018 | |
TargaGenix Inc.
|
was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity. | $100K / Seed / Sep 16, 2018 | |
Epivax Oncology
|
EpiVax Oncology is a provider of a clinical research and development platform intended to offer various type of precision cancer immunotherapies. The company's platform are based on optimal neo-epitopes selected through its proprietary and validated, in-silico, predictive algorithms, enabling clients to address the unmet medical needs that areinadequately addressed by current cancer therapeutic approaches. | $1.2M / Jun 12, 2018 | |
| See all 22 investments → | |||
Co-Investors
AJI Capital
4 deals together
Arizona Tech Investors
1 deal together
Belmond Capital
1 deal together
Empire Angels
1 deal together
Techstars Chicago
1 deal together
Farfetch
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Accelerate New York Seed Fund invest in?
Accelerate New York Seed Fund invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Seed and Pre-Seed stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Accelerate New York Seed Fund?
Public channels for Accelerate New York Seed Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Accelerate New York Seed Fund?
The team at Accelerate New York Seed Fund includes Peter Donnelly (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
